Viral load, CD4 percentage, and delayed-type hypersensitivity in subjects receiving the HIV-1 immunogen and antiviral drug therapy

Journal of Clinical Immunology

Volumn 16, Issue 5, 1996, Pages 266-271

  Moss, Ronald B ^a   Ferre, Francois ^a   Levine, Alexandra ^b   Turner, John ^c   Jensen, Fred C ^a   Daigle, Anne E ^a   Richieri, Steven P ^a   Truckenbrod, Allison ^a   Trauger, Richard J ^a   Carlo, Dennis J ^a   Salk, Jonas ^d  

^a Orchestra Therapeutics Inc   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c GRADUATE HOSPITAL   (United States)

^d SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

antivirals; CD4; delayed type hypersensitivity; HIV 1 immunogen; viral load

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; PRIORITY JOURNAL;

AIDS VACCINES; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DRUG THERAPY, COMBINATION; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HYPERSENSITIVITY, DELAYED; IMMUNOTHERAPY, ACTIVE; VIRAL LOAD; ZIDOVUDINE;

EID: 10144226387     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01541391     Document Type: Article

References (23)

1. Rinaldo C, Huang X, Fan Z, et al. High levels of anti-HIV type I memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected longterm non-progressors. J Virol 69:5838-5842, 1995
2. Clerici M, Landay AL, Kessler HA, et al.: Reconstitution of long-term T helper cell function after zidovudine therapy in HIV-infected patients. J Infect Dis 166:723-730, 1992
3. Loveday C, Kaye S, Tenant-Flowers M, et al.: HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy. Lancet 345:820-824, 1995
4. Havlir D, Richman DD: Antiviral therapy. Curr Opin Infect Dis 8:66-73, 1995
5. Kovacs JA, Baseler M, Dewar RJ, et el.: Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Engl J Med 332:567-574, 1995
6. Salk J: Prospects for the control of AIDS by immunizing seropositive individuals. Nature 327:473-476, 1987
7. Gibbs Jr. CJ, Peters R, Gravell M, et al.: Observations after human immunodeficiency virus immunization and challenge of human immunodeficiency virus seropositive and seronegative chimpanzees. Proc Natl Acad Sci USA 88:3348-3352, 1991
8. Levine AM, Groshen S, Allen J, et al.: Initial studies of active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: Long term follow-up. J AIDS Hum Retroviral 11:351-364, 1996
9. Trauger RJ, Ferre F, Daigle AE, et al.: Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type I (HIV-1) Immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells. J Infect Dis 169:1256-1264, 1994
10. Turner JL, Trauger RJ, Daigle AE, Carlo DJ: HIV-1 Immunogen induction of HIV-1-specific delayed-type hypersensitivity: Results of a double-blind, adjuvant-controlled, dose-ranging trial. AIDS 8:1429-1435, 1994
11. Ferre F, Marchese AL, Griffin SL: Development and validation of a polymerase chain reaction method for the precise quantification of HIV-1 DNA in blood cells from subjects undergoing a 1-year immunotherapeutic treatment. AIDS 7 (Suppl 2):s21-s27, 1993
12. Trauger RJ, Daigle AE, Giermakowska W, Moss RB, Jensen F, Carlo DJ: Safety and immunogenicity of a gp120-depleted inactivated HIV-1 Immunogen: Results of a double-blind, adjuvant-controlled study. J AIDS 10 (Suppl 2):S74-S82, 1995
13. Luque F, Caruz A, Pineda JA, et al.: Provirus load changes in untreated and zidovudine-treated human immunodeficiency virus type-1 infected patients. J Infect Dis 169:267-273, 1994
14. Hughes M, et al.: Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: Implications for patient monitoring. J Infect Dis 169:28-36, 1994
15. Burcham J, et al.: CD4% is the best predictor of development of AIDS in a cohort of HIV-infected homosexual men. AIDS 5:S365-S372, 1991
16. Salk P, Salk J: Cell-mediated immunologie memory in prevention and treatment of HIV disease. Res Immunol 145:629-633, 1994
17. Shearer G, et al.: Cellular immunity to HIV antigens in HIV-infected individuals and in seronegative, exposed health care workers. Abstract submitted for American Association of Immunologists (AAI) meeting in New Orleans, LA, June 1996
18. O'Brien WA, Grovit-Ferbas K, Namazi A, et al.: HIV type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 86:1082-89, 1995.
19. Ferre F, Moss RB, Daigle AE, Richieri SP, Jensen FC, Carlo DJ: Viral load in peripheral blood mononuclear cells as surrogate for clinical progression. J AIDS 10 (Suppl 2):S51-S56, 1995
20. Kitchen VS, Skinner C, Ariyoshi C, et al.: Safety and activity of saquinavir in HIV infection. Lancet 345:952-955, 1995
21. Eberle J, Bechowsky B, Rose D, et al.: Resistance of HIV type 1 protease inhibitor RO 31-8959. AIDS Res Hum Retrovirus 11: 671-676, 1995
22. Condra J, Schleif W, Blahy O, et al.: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571, 1995
23. Tisdale M, Myers RE, Maschera B, Parry NR, Oliver NM, Blair ED: Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother 39:1704-1710, 1995